Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07363486 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: 225Ac-LNC1011

Sponsor

First Affiliated Hospital of Fujian Medical University